Molecular mechanisms of pulmonary arterial remodeling

Molecular Medicine

Volumn 20, Issue 1, 2014, Pages 191-201

  Crosswhite, Patrick ^a   Sun, Zhongjie ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; DICHLOROACETIC ACID; ENDOTHELIN 1; FOUR AND A HALF LIM DOMAIN PROTEIN 1; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIM PROTEIN; NITRIC OXIDE; NOTCH3 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PLACEBO; PLATELET DERIVED GROWTH FACTOR; POTASSIUM CHANNEL; PROSTACYCLIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTERIOLE; ARTERY MUSCLE; ARTICLE; CELL PROLIFERATION; DRUG TARGETING; DRUG WITHDRAWAL; EPIGENETICS; HEMATOMA; HUMAN; LUNG ARTERY PRESSURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY ARTERIAL REMODELING; PULMONARY ARTERY; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL PROLIFERATION; EPIGENESIS, GENETIC; HUMANS; HYPERTENSION, PULMONARY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; TRANSCRIPTION FACTORS;

EID: 84899137231     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2013.00165     Document Type: Article

References (97)

1. Anderson JR, Nawarskas JJ. (2010) Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol. Rev. 18:148-62.
2. Morrell NW, et al. (2009) Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54:S20-31.
3. Giaid A, Saleh D. (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333:214-21.
4. Szczeklik J, et al. (1978) Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension. Br. Heart J. 40:1397-401.
5. Christman BW, et al. (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327:70-5.
6. Stewart DJ, Levy RD, Cernacek P, Langleben D. (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med. 114:464-9.
7. Launay JM, et al. (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 8:1129-35.
8. Eddahibi S, et al. (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation. 113:1857-64.
9. Uchida S, et al. (2009) An integrated approach for the systematic identification and characterization of heart-enriched genes with unknown functions. BMC Genomics. 10:100.
10. Savoia C, et al. (2011) Vascular inflammation and endothelial dysfunction in experimental hypertension. Int. J. Hypertens. 2011:281240.
11. Crosswhite P, Sun Z. (2010) Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J. Hypertens. 28:201-12.
12. Balabanian K, et al. (2002) CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 165:1419-25.
13. Gomez-Arroyo JG, et al. (2011) The monocrotaline model of pulmonary hypertension in perspective. Am. J. Physiol. Lung Cell. Mol. Physiol. 302:L363-9.
14. Ghamra ZW, Dweik RA. (2003) Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleve Clin. J. Med. 70 Suppl 1:S2-8.
15. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. (2011) Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 8:443-55.
16. Humbert M, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43:13S-24S.
17. Jeffery TK, Morrell NW. (2002) Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog. Cardiovasc. Dis. 45:173-202.
18. Bouallegue A, Daou GB, Srivastava AK. (2007) Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr. Vasc. Pharmacol. 5:45-52.
19. Clapp LH, et al. (2002) Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell Moll. Biol. 26:194-201.
20. Owen NE. (1986) Effect of prostaglandin E1 on DNA synthesis in vascular smooth muscle cells. Am. J. Physiol. 250:C584-8.
21. Nilsson J, Olsson AG. (1984) Prostaglandin E1 inhibits DNA synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor. Atherosclerosis. 53:77-82.
22. Jourdan KB, Evans TW, Lamb NJ, Goldstraw P, Mitchell JA. (1999) Autocrine function of inducible nitric oxide synthase and cyclooxygenase-2 in proliferation of human and rat pulmonary artery smooth-muscle cells: species variation. Am. J. Respir. Cell Mol. Biol. 21:105-10.
23. Rich S, et al. (2010) Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest. 138:1234-9.
24. Deng Z, et al. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67:737-44.
25. Lane KB, et al. (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat. Genet. 26:81-4.
26. Trembath RC, et al. (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 345:325-34.
27. Chaouat A, et al. (2004) Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 59:446-8.
28. Massague J, Chen YG. (2000) Controlling TGFbeta signaling. Genes. Dev. 14:627-44.
29. Beppu H, et al. (2000) BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev. Biol. 221:249-58.
30. Du L, et al. (2003) Signaling molecules in nonfamilial pulmonary hypertension. N. Engl. J. Med. 348:500-9.
31. Markewitz BA, Farrukh IS, Chen Y, Li Y, Michael JR. (2001) Regulation of endothelin-1 synthesis in human pulmonary arterial smooth muscle cells. Effects of transforming growth factor-beta and hypoxia. Cardiovasc. Res. 49:200-6.
32. Barst RJ. (2007) A review of pulmonary arterial hypertension: role of ambrisentan. Vasc. Health Risk Manag. 3:11-22.
33. Zuckerbraun BS, et al. (2007) Nitric oxide-induced inhibition of smooth muscle cell proliferation involves S-nitrosation and inactivation of RhoA. Am. J. Physiol. Cell Physiol. 292:C824-31.
34. Landsberg JW, Yuan JX. (2004) Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation. News Physiol. Sci. 19:44-50.
35. Berridge MJ. (1993) Inositol trisphosphate and calcium signalling. Nature. 361:315-25.
36. Yang XR, Lin MJ, Sham JS. (2010) Physiological functions of transient receptor potential channels in pulmonary arterial smooth muscle cells. Adv. Exp. Med. Biol. 661:109-22.
37. Inoue R, et al. (2001) The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. Circ. Res. 88:325-32.
38. Slish DF, Welsh DG, Brayden JE. (2002) Diacylglycerol and protein kinase C activate cation channels involved in myogenic tone. Am. J. Physiol. Heart Circ. Physiol. 283:H2196-201.
39. Yuan JX, et al. (1998) Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 98:1400-6.
40. Geraci MW, et al. (2001) Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ. Res. 88:555-62.
41. Joshi S, Sedivy V, Hodyc D, Herget J, Gurney AM. (2009) KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J. Pharmacol Exp. Ther. 329:368-76.
42. Huang RP, et al. (1999) Tumor promotion by hydrogen peroxide in rat liver epithelial cells. Carcinogenesis. 20:485-92.
43. Zhang S, et al. (2003) Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 285:L740-54.
44. McMurtry MS, et al. (2004) Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 95:830-40.
45. Liu H, Nishitoh H, Ichijo H, Kyriakis JM. (2000) Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptorassociated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol. Cell. Biol. 20:2198-208.
46. Kim GH, Ryan JJ, Marsboom G, Archer SL. (2011) Epigenetic mechanisms of pulmonary hypertension. Pulm. Circ. 1:347-56.
47. Xu XF, Cheng F, Du LZ. (2011) Epigenetic regulation of pulmonary arterial hypertension. Hypertens. Res. 34:981-6.
48. Archer SL, et al. (2010) Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation. 121:2661-71.
49. Xu XF, et al. (2011) Epigenetic regulation of the endothelial nitric oxide synthase gene in persistent pulmonary hypertension of the newborn rat. J. Hypertens. 28:2227-35.
50. White K, Loscalzo J, Chan SY. (2012) Holding our breath: The emerging and anticipated roles of microRNA in pulmonary hypertension. Pulm. Circ. 2:278-90.
51. Parikh VN, et al. (2012) MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation. 125:1520-32.
52. Steiner MK, et al. (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104:236-44.
53. Yang S, et al. (2012) miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am. J. Physiol. Lung Cell. Mol. Physiol. 302:L521-9.
54. Sarkar J, et al. (2010) MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am. J. Physiol. Lung Cell. Mol. Physiol. 299:L861-71.
55. Kang K, et al. (2013) MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. J. Biol. Chem. 288:25414-27.
56. Jalali S, et al. (2012) Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS One. 7:e46808.
57. Gou D, et al. (2012) miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 303:L682-91.
58. Courboulin A, et al. (2011) Role for miR-204 in human pulmonary arterial hypertension. J. Exp. Med. 208:535-48.
59. Meloche J, et al. (2014) Role for DNA damage sig-naling in pulmonary arterial hypertension. Circulation. 129:786-97.
60. Drake KM, et al. (2011) Altered microRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. Am. J. Respir. Crit. Care Med. 184:1400-8.
61. Kim J, et al. (2013) An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat. Med. 19:74-82.
62. Grant JS, White K, MacLean MR, Baker AH. (2013) MicroRNAs in pulmonary arterial remodeling. Cell. Mol. Life Sci. 70:4479-94.
63. Meloche J, Paulin R, Provencher S, Bonnet S. (2013) Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Curr. Vasc. Pharmacol. 2013, May 13. [Epub ahead of print]
64. Paulin R, Courboulin A, Barrier M, Bonnet S. (2011) From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. J Mol. Med. (Berl). 89:1089-101.
65. Grimminger F, Schermuly RT. (2010) PDGF receptor and its antagonists: role in treatment of PAH. Adv. Exp. Med. Biol. 661:435-46.
66. Grotendorst GR, Chang T, Seppa HE, Kleinman HK, Martin GR. (1982) Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J. Cell. Physiol. 113:261-6.
67. Ross R, Glomset J, Kariya B, Harker L. (1974) A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc. Natl. Acad. Sci. U. S. A. 71:1207-10.
68. Schermuly RT, et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115:2811-21.
69. Humbert M, et al. (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur. Respir. J. 11:554-9.
70. Yu Y, et al. (2003) PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am. J. Physiol. Cell Physiol. 284:C316-30.
71. Balasubramaniam V, et al. (2003) Role of plateletderived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am. J. Physiol. Lung Cell. Mol. Physiol. 284:L826-33.
72. Jankov RP, et al. (2005) A role for platelet-derived growth factor beta-receptor in a newborn rat model of endothelin-mediated pulmonary vascular remodeling. Am. J. Physiol. Lung Cell. Mol. Physiol. 288:L1162-70.
73. Ghofrani HA, Seeger W, Grimminger F. (2005) Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 353:1412-3.
74. Hoeper MM, et al. (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 127:1128-38.
75. Mucke H. (2013) The role of imatinib in the treatment of pulmonary hypertension. Drugs Today. (Barc). 49:203-11.
76. Clifford RL, Deacon K, Knox AJ. (2008) Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, AND GSK3(beta). J. Biol. Chem. 283:35337-53.
77. Hassoun PM, et al. (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54:S10-9.
78. Partovian C, et al. (1998) Heart and lung VEGF mRNA expression in rats with monocrotaline-or hypoxia-induced pulmonary hypertension. Am. J. Physiol. 275:H1948-56.
79. Campbell AI, Zhao Y, Sandhu R, Stewart DJ. (2001) Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation. 104:2242-8.
80. Partovian C, et al. (2000) Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am. J. Respir. Cell Mol. Biol. 23:762-71.
81. Mata-Greenwood E, Grobe A, Kumar S, Noskina Y, Black SM. (2005) Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-beta1 and reactive oxygen species: a requirement for NAD(P)H oxidase. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L288-9.
82. Mata-Greenwood E, Meyrick B, Soifer SJ, Fineman JR, Black SM. (2003) Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol 285: L222-31.
83. Firth AL, Yao W, Remillard CV, Ogawa A, Yuan JX. (2010) Upregulation of Oct-4 isoforms in pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 298:L548-57.
84. Greco SJ, Liu K, Rameshwar P. (2007) Functional similarities among genes regulated by OCT4 in human mesenchymal and embryonic stem cells. Stem Cells. 25:3143-54.
85. Yoshida T, Kaestner KH, Owens GK. (2008) Conditional deletion of Kruppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury. Circ. Res. 102:1548-57.
86. Freyd G, Kim SK, Horvitz HR. (1990) Novel cysteine-rich motif and homeodomain in the product of the Caenorhabditis elegans cell lineage gene lin-11. Nature. 344:876-9.
87. Kwapiszewska G, et al. (2008) Fhl-1, a new key protein in pulmonary hypertension. Circulation. 118:1183-94.
88. Bonnet S, et al. (2006) An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 113:2630-41.
89. Semenza GL. (2005) Pulmonary vascular responses to chronic hypoxia mediated by hypoxia-inducible factor 1. Proc. Am. Thorac. Soc. 2:68-70.
90. Li X, et al. (2009) Notch3 signaling promotes the development of pulmonary arterial hypertension. Nature Med. 15:1289-97.
91. Campos AH, Wang W, Pollman MJ, Gibbons GH. (2002) Determinants of Notch-3 receptor expression and signaling in vascular smooth muscle cells: implications in cell-cycle regulation. Circ. Res. 91:999-1006.
92. Morrow D, et al. (2005) Notch-mediated CBF-1/RBP-J{kappa}-dependent regulation of human vascular smooth muscle cell phenotype in vitro. Am. J. Physiol. Cell Physiol. 289:C1188-96.
93. Wang W, Prince CZ, Mou Y, Pollman MJ. (2002) Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J Biol. Chem. 277:21723-9.
94. Berset T, Hoier EF, Battu G, Canevascini S, Hajnal A. (2001) Notch inhibition of RAS signaling through MAP kinase phosphatase LIP-1 during C. elegans vulval development. Science 291:1055-8.
95. Lowery JW, et al. (2010) ID family protein expression and regulation in hypoxic pulmonary hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299:R1463-77.
96. Perk J, Iavarone A, Benezra R. (2005) Id family of helix-loop-helix proteins in cancer. Nat. Rev. Cancer. 5:603-14.
97. Yang J, et al. (2010) Smad-dependent and smadindependent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ. Res. 107:252-62.